A standard eczema routine is an emollient used every day and a topical steroid stepped up or down with severity. That is the right foundation, and where it stalls the reasons are usually structural rather than pharmacological. The appointment is short, the topical treatment is applied far less often than it was prescribed, the steroid itself is feared, and the emollient is used at a fraction of the quantity guidance assumes. Each of those has been measured.
Ten minutes is the appointment, not the treatment
A systematic review of primary care consultation length covering 179 studies, 28,570,712 consultations and 67 countries put the most recent UK measurement at 9.22 minutes, recorded in 2014 (Irving et al, 2017).
Confirming the diagnosis, choosing a potency, explaining application and dealing with whatever else the patient arrived with all happen inside that. What does not fit is the part that decides whether the routine works: how much emollient goes on, at what point after washing, on which days, and what preceded each flare. The last of those is not an appointment task at all. It takes weeks of the patient's own observation, which is what an eczema food diary or a record of stress and flare timing exists to collect. Referral to dermatology buys a longer appointment and access to treatments a GP cannot start. Some of what a ten-minute consultation cannot cover is carried by charities and helplines instead, and the UK ones are listed in eczema support in the UK.
The prescribed dose and the applied dose are different numbers
Krejci-Manwaring and colleagues gave 37 children with atopic dermatitis 0.1% triamcinolone ointment to apply twice daily over eight weeks. Electronic monitors recorded every opening of the container, and families were not told until the study ended. Among the 26 who completed it, mean adherence across the eight weeks was 32% (Krejci-Manwaring et al, 2007).
The pattern inside it matters as much as the number. "Adherence was higher on or near office visit days and subsequently decreased rapidly." Use climbs before a review and falls away after it, so the clinician sees the treatment at close to its best while the skin gets it at its worst. A steroid applied a third of the time is then judged as though it had been applied fully. The conclusion drawn is that the treatment does not work, when the dose the trial evidence rests on was never delivered.
Fear of the steroid changes how it gets used
Li, Yin and Antaya screened 490 articles and included 16 cross-sectional studies of topical corticosteroid phobia in atopic dermatitis. Reported prevalence ran from 21.0% (95% CI 15.8 to 26.2) up to 83.7% (95% CI 81.9 to 85.5), so the figure depends heavily on the population surveyed and the instrument used (Li et al, 2017).
In the studies comparing the two groups, non-adherence ran at 49.4% against 14.1%, and at 29.3% against 9.8%, in the phobia and non-phobia cohorts. Fear rarely presents as refusal. It presents as a thinner layer, a shorter course, or stopping at the first sign of improvement, which lets the flare return and appears to confirm the fear. NICE matches potency to severity rather than defaulting to the weakest option: mild potency for mild eczema, moderate for moderate, potent for severe (NICE CG57). What a steroid does, and what it leaves untouched, is covered in steroid creams for eczema.
The emollient quantity in the guideline is larger than most people picture
NICE tells prescribers to "prescribe large quantities of leave-on emollients (250 g to 500 g weekly)" for children with atopic eczema, and says they should be used "in larger amounts and more often than other treatments on their whole body, both when the atopic eczema is clear and while using all other treatments" (NICE CG57).
500 g a week is about 70 g a day, one 500 g pump dispenser a week. A 100 g tube at that rate is gone in a day and a half. Someone working through one small tube a month is at a fraction of the dose the guidance describes, not a gentler version of the same routine. An emollient holds water in and replaces lipid only while it is physically on the skin, so quantity and frequency are the dose. Timing is the other half of it, and that is set out in how to moisturise eczema.
Where the ladder stalls
NICE frames management as a stepped approach, emollients as the constant base with other treatments added or withdrawn as severity changes. Referral is urgent, within two weeks, when eczema "is severe and has not responded to optimal topical therapy after 1 week", and routine when "management has not controlled the atopic eczema satisfactorily" or it "is causing significant social or psychological problems" (NICE CG57).
Both directions of that ladder assume the current step is being delivered as written. At 32% adherence, and with emollient at a fraction of the stated quantity, optimal topical therapy has not really been attempted, so the failure that would trigger a step up never gets established and neither does control. The routine settles in the middle: enough to blunt the worst of it, not enough to settle the skin, and no clean evidence either way. For people who do work through the topical and systemic steps, biologics and JAK inhibitors sit above them in the NHS sequence, and which of those drugs is offered first is decided by the NICE appraisal covering each one.
What an optimised routine actually is
An optimised routine is not a different set of products. It is the prescribed one delivered at the quantity, frequency and duration the guidance describes, recorded well enough to show whether it was.
In practice that means emollient measured against the 250 to 500 g weekly figure rather than estimated by eye, applied while the skin is still damp after washing. It means the potency matched to severity, with the course followed as prescribed rather than abandoned at the first improvement. And it means a written record of what went on, when, and what the skin did next. Trigger tracking turns that record into something a ten-minute appointment can act on, because the history arrives already collected. The full sequence is set out in the protocol walkthrough.
References
- Irving G, Neves AL, Dambha-Miller H, et al. International variations in primary care physician consultation time: a systematic review of 67 countries. BMJ Open, 2017, 7:e017902. https://pmc.ncbi.nlm.nih.gov/articles/PMC5695512/
- Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. Journal of the American Academy of Dermatology, 2007, 56:211-216. https://doi.org/10.1016/j.jaad.2006.05.073
- Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatology, 2017, 153(10):1036. https://doi.org/10.1001/jamadermatol.2017.2437
- National Institute for Health and Care Excellence. Atopic eczema in under 12s: diagnosis and management. Clinical guideline CG57. https://www.ncbi.nlm.nih.gov/books/NBK571009/